For instance, higher ORRs were reported in other phase 2 trials evaluating RT with pembrolizumab in patients with metastatic NSCLC (36%, PEMBRO-RT, NCT02492568; ref. 18) and metastatic TNBC (17.6%, NCT02730130) regardless of PD-L1 status (15); however, patients in these studies were naïve to CPIs, so a direct comparison cannot be made. This evidence concerns the gene CD274 and non-small cell lung carcinoma.